ALLMedicine™ Hypertriglyceridemia Center

May 20th, 2022 - Leptin is an adipocyte-derived hormone that can be thought of as a signal from adipose tissue to the rest of the body conveying information about long-term nutritional status. Patients with the very rare condition of generalized lipodystrophy have...

May 18th, 2022 - Acute pancreatitis in pregnancy (APIP) is a rare and serious complication during pregnancy. It has acute onset and is difficult to diagnose and treat. The aim of the present study was to describe the etiology, clinical manifestations, and maternof...

May 16th, 2022 - This will be a multi-center, randomized, double-blind, placebo-controlled study in approximately 112 participants with hypertriglyceridemia and established or at increased risk for atherosclerotic cardiovascular disease, and/or with severe hypertr...

May 14th, 2022 - Patients with newly diagnosed acute promyelocytic leukemia (APL) are often obese or overweight, accompanied by metabolic disorders, such as dyslipidemia. However, the link between dyslipidemia and leukemia is obscure. Here, we conducted a retrospe...

May 9th, 2022 - Like obesity, NAFLD and NASH are closely linked to nutrition and the "Western diet" which is rich in saturated fats and refined sugars. Although fat consumption has remained relatively stable, the marked increase in dietary fructose consumption (m...

Aug 2nd, 2021 - 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee.|2021|Virani SS,Morris PB,Agarwa...

Mar 27th, 2020 - Dyslipidemias are common and increase the risk of cardiovascular disease. The menopause transition is associated with an atherogenic lipid profile, with an increase in the concentrations of total cholesterol (TC) and low-density lipoprotein choles...

May 20th, 2022 - Leptin is an adipocyte-derived hormone that can be thought of as a signal from adipose tissue to the rest of the body conveying information about long-term nutritional status. Patients with the very rare condition of generalized lipodystrophy have...

May 16th, 2022 - This will be a multi-center, randomized, double-blind, placebo-controlled study in approximately 112 participants with hypertriglyceridemia and established or at increased risk for atherosclerotic cardiovascular disease, and/or with severe hypertr...

May 9th, 2022 - Like obesity, NAFLD and NASH are closely linked to nutrition and the "Western diet" which is rich in saturated fats and refined sugars. Although fat consumption has remained relatively stable, the marked increase in dietary fructose consumption (m...

May 9th, 2022 - Study process is as follows. Informed consent for subjects fulfilling the inclusion criteria. Laboratory evaluation will be done for subjects according to the following diagnostic criteria. Diagnosis will be established if one of either 1 or 2 bel...

May 2nd, 2022 - INTRODUCTION Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in developed countries affecting approximately 30 % of the general adult population. The disease is defined by an increased fat accumulation in...

May 2nd, 2022 - The FDA has issued a complete response letter (CRL) to the new drug application (NDA) seeking the approval of surufatinib for the treatment of patients with pancreatic and extra-pancreatic neuroendocrine tumors (NETs), according to an announcement...

Mar 23rd, 2022 - Patients who have had a stroke or transient ischemic attack (TIA) of atherothrombotic origin and have high triglyceride levels are at increased risk of having further cardiovascular events, including a recurrent stroke, even if they are taking sta...

Feb 18th, 2022 - This transcript has been edited for clarity. I'm Dr Neil Skolnik and today I'm going to talk about the American Heart Association's (AHA's) latest guidelines on the management of elevated triglycerides. This is important because even when high LDL...

Feb 14th, 2022 - The addition of dalpiciclib (SHR6390) to fulvestrant (Faslodex) significantly prolonged progression-free survival (PFS) vs fulvestrant alone in patients with hormone receptor (HR)–positive, HER2-negative advanced breast cancer, according to data f...

Jan 28th, 2022 - The European Commission has granted a marketing authorization for lorlatinib (Lorviqua) for use as a single agent in the treatment of adult patients with ALK-positive advanced non–small cell lung cancer (NSCLC) who did not receive a prior ALK inhi...